COMMUNIQUÉS West-GlobeNewswire

Novartis data shows half of eligible Ph+ CML-CP patients remain in Treatment-free Remission nearly two years after stopping Tasigna®
23/06/2017
New 96-week data support durability and safety of Treatment-free Remission (TFR) in Ph+ CML-CP patients who stop taking Tasigna [1,2] More than 90% of Ph+ CML-CP patients in ENESTfreedom and ENESTop who stopped Tasigna [...]
Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL
23/06/2017
83% of patients achieved complete remission (CR) or CR with incomplete blood count recovery within 3 months of treatment with CTL019; consistent with interim ELIANA data Data evaluating 63 patients demonstrate relapse- [...]
Virbac :Sébastien Huron deviendra le président du directoire du groupe Virbac fin 2017
23/06/2017
Sébastien Huron deviendra le président du directoire du groupe Virbac fin 2017 Carros, France - Le 23 juin 2017 Virbac annonce l'intention du conseil de surveillance de nommer Sébastien Huron président du directoire de [...]
Virbac : Sébastien Huron will become the new chairman of the executive board as of December 2017
23/06/2017
Virbac group: Sébastien Huron will become the new chairman of the executive board as of December 2017 Carros, France - June 23, 2017 Virbac has announced the supervisory board's intention to appoint Sébastien Huron as [...]
GENFIT franchit une étape décisive pour le développement d'un test de diagnostic in-vitro (IVD) non-invasif dans la NASH
23/06/2017
GENFIT franchit une étape décisive pour le développement d'un test de diagnostic in-vitro (IVD) non-invasif dans la NASH Achèvement de la phase de faisabilité du programme de biomarqueurs dans la NASH après confirmation [...]
GENFIT Reaches a Critical Milestone towards the Development of a Non-Invasive In Vitro Diagnostic (IVD) Test for NASH
23/06/2017
GENFIT Reaches a Critical Milestone towards the Development of a Non-Invasive In Vitro Diagnostic (IVD) Test for NASH Completion of the NASH biomarker program feasibility phase, after confirmation of the competitive [...]
DiaSorin and Tecan to collaborate in new platform development
23/06/2017
Saluggia, Italy and Männedorf, Switzerland, June 23, 2017 - DiaSorin (FTSE Italy Mid Cap: DIA) and Tecan Group (SIX Swiss Exchange: TECN) announced today that they have agreed to collaborate in a development under which [...]
TiGenix to present at the 7th TERMIS-EU Conference in Davos, Switzerland
23/06/2017
PRESS RELEASE TiGenix to present at the 7 th TERMIS-EU Conference in Davos, Switzerland Leuven (BELGIUM) - June 23, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical [...]
Présentation de TiGenix à l'occasion de la 7ème Conférence TERMIS-UE à Davos (Suisse)
23/06/2017
COMMUNIQUÉ DE PRESSE Présentation de TiGenix à l'occasion de la 7 ème Conférence TERMIS-UE à Davos (Suisse) Louvain (BELGIQUE) - vendredi 23 juin 2017, 07h. CEST - TiGenix NV (Euronext Brussels et NASDAQ : TIG), société [...]
Addex Shareholders Approved all Board Proposals at 2017 Annual General Meeting
23/06/2017
Roger Mills elected to the Addex Board of Directors Geneva, Switzerland, 23 June 2017 - Addex Therapeutics (SIX: ADXN), announced today that its shareholders approved all the proposals of the board of directors at its [...]
Novartis combination targeted therapy Tafinlar® + Mekinist® receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)
22/06/2017
Approval provides first targeted treatment in the US specifically for BRAF V600E mutation-positive metastatic NSCLC More than 60% of treatment-naïve and previously treated patients with BRAF V600E mutant metastatic [...]
Targovax ASA: Mandatory notification of trade by primary insider in relation to exercise of employee options
22/06/2017
1. Exercise of employee share options Berit Iversen, VP CMC of Targovax (the "Primary Insider"), has on 22 June 2017 subscribed for 25,000 shares in Targovax ASA at a price of NOK 7.5 per share in connection with her [...]
Novo Nordisk A/S: CHMP endorses EU label update of Saxenda® based on the LEADER trial
22/06/2017
PR170622_LEADER_EU_CHMP_Saxenda_UK This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 mai 2017
22/06/2017
Communiqué de presse Villepinte, le 22 juin 2017 DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l' [...]
AB Science présente de nouvelles données positives de son étude de phase 3 dans la mastocytose systémique sévère au 22ème Congrès international de de l'Association Européenne d'Hématologie (AEH)
22/06/2017
Paris, 22 juin, 17h45 AB Science présente de nouvelles données positives de son étude de phase 3 dans la mastocytose systémique sévère au 22ème Congrès international de de l'Association Européenne d'Hématologie (AEH) Le [...]
AB Science Presents Supportive Data from its Phase 3 Study in Severe Systemic Mastocytosis at the 22nd Congress of the European Hematology Association (EHA)
22/06/2017
Paris, June 22, 2017, 5.45pm AB Science Presents Supportive Data from its Phase 3 Study in Severe Systemic Mastocytosis at the 22 nd Congress of the European Hematology Association (EHA) Abstract Selected for [...]
Minerva Announces Completion of Bridging Study to Select Improved Formulation of MIN-101 for Use in Phase 3 Trial for the Treatment of Negative Symptoms in Patients With Schizophrenia
22/06/2017
New formulation observed to improve safety margin while offering bioequivalent exposure to prior formulation Company to proceed with initiation of Phase 3 trial on schedule in second half of 2017 CMC scale-up work for [...]
Auris Medical to Host Scientific Symposium at IFOS ENT World Congress in Paris
22/06/2017
Zug, Switzerland, June 22, 2017 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced [...]
Oriola Corporation has rearranged its long-term revolving credit facility and term loan agreement
22/06/2017
Oriola Corporation Stock Exchange Release 22 June 2017 at 15.00 Oriola Corporation has rearranged its long-term revolving credit facility and term loan agreement Oriola Corporation has agreed to rearrange its long-term [...]

Pages